Product
LYB002CA
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
To Evaluate the Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Trivalent Vaccine (CHO Cell) LYB002 in Chinese Adults 18 Years and Above Completed Three-dose Inactivated COVID-19 VaccineStatus: Active (not recruiting), Estimated PCD: 2023-07-31